Catalyst Wire Dossier Catalyst Wire Dossier

Next-generation hormonal agent (NHA)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Next-generation hormonal agent (NHA), covering 2025-12-30 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) [Phase 3]

See pricing